(Q35974612)

11 August 2017

title

Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer (English)

1 reference

11 August 2017

1 reference

Snehal M Bhoola

1

1 reference

11 August 2017

Robert L Coleman

2

1 reference

11 August 2017

Thomas Herzog

3

1 reference

11 August 2017

Robert Morris

4

1 reference

11 August 2017

Christopher Bryant

5

1 reference

11 August 2017

Jacob M Estes

6

1 reference

11 August 2017

Ronald D Alvarez

7

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

95

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

564-569

1 reference

11 August 2017

cites work

Advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.026

Update on the role of topotecan in the treatment of recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.026

Relapsed ovarian cancer: challenges and management strategies for a chronic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.026

Management of treatment-related toxicity in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.026

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.026

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.026

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.026

Phase I and pharmacologic study of topotecan in patients with impaired renal function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.026

Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.026

Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.026

CA125 response: can it replace the traditional response criteria in ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.026

Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.026

Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.026

Comparative activity of oral and parenteral topotecan in murine tumor models: efficacy of oral topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.026

Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.026

A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.026

A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.026

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.026

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2004.08.026

1 reference

11 August 2017

1 reference